Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
175 hedge funds and large institutions have $1.95B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 71 increasing their positions, 47 reducing their positions, and 43 closing their positions.
586% more call options, than puts
Call options by funds: $118M | Put options by funds: $17.1M
51% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 47
7% less funds holding
Funds holding: 188 → 175 (-13)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
21% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 43
27% less capital invested
Capital invested by funds: $2.67B → $1.95B (-$715M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$141M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$106M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$72.2M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$26.6M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$25.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$32.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$24.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$13.8M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$12.8M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.2M |
BHVN Hedge Fund Activity: Q1 2020 in Review
175 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2020, worth a combined $1.95B — down 27% from $2.67B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of BHVN and 34 opened new positions — a net loss of 9 holders — while 47 trimmed existing stakes and 71 added.
The largest buyer was Capital International Investors, adding an estimated $141M. The largest seller was Adage Capital Partners, cutting an estimated $32.1M.
- 175 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2020, down from 188 in Q4 2019.
- Funds reported $1.95B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2020, down 27% quarter-over-quarter.
- 34 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2020 and 43 closed out, a net change of -9 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2020 was Capital International Investors, an estimated $141M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2020 was Adage Capital Partners, an estimated $32.1M sold.
Based on aggregated 13F filings for Q1 2020.